Abstract
GVHD is the major limitation to human allogeneic bone marrow transplantation (BMT). A murine model of BMT was developed to study acute and chronic GVHD due to non-major histocompatibility region (MHR) antigens. Lethally irradiated C57B1/6 mice were transplanted with bone marrow and spleen cells from LP mice. When recipients were transplanted with 1-10 × 106 spleen cells in addition to 10 × 106 bone marrow cells, 31 of 91 animals developed acute GVHD, 19 chronic GVHD, and 41 no GVHD. The in vitro removal of mature T lymphocytes by treatment with a monoclonal antibody to murine T lymphocytes and complement eliminated GVHD in all of 50 recipients. Recipient mice developed normal hematocrits, adult hemoglobin electrophoretic patterns, and normal T cell function by three months. Human bone marrow cells treated with a monoclonal antibody to mature T lymphocytes (OKT-3) and complement had no residual detectable T cells as determined by E-rosette formation (16% pretreatment; 0%, post-treatment) or by indirect immunofluorescence(17% pre; 0% post). The total number of nucleated cells was reduced by 50% during treatment with no decrease in the frequency of hematopoietic precursors (BFU-E colonies). The use of monoclonal antibodies to remove mature T lymphocytes from human bone marrow may be an effective method to prevent human GVHD.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hamilton, B., Lipton, J. & Parkman, R. 922 TREATMENT OF MURINE AND HUMAN BONE MARROW WITH MONO-CLONAL ANTIBODIES TO T LYMPHOCYTES TO PREVENT GRAFT VERSUS HOST DISEASE (GVHD). Pediatr Res 15 (Suppl 4), 596 (1981). https://doi.org/10.1203/00006450-198104001-00947
Issue Date:
DOI: https://doi.org/10.1203/00006450-198104001-00947